Xeris Biopharma Holdings (XERS) EBITDA Margin (2020 - 2026)

Xeris Biopharma Holdings has reported EBITDA Margin for 7 years, with the latest figure at 2.69% in Q1 2026.

• For the quarter ending Q1 2026, EBITDA Margin rose 1802.0% year-over-year to 2.69%; the trailing twelve-month figure through Mar 2026 stood at 3.81% (up 2406.0% YoY), and the FY2025 full-year result was 0.19%, up 2719.0% from the prior year.
• EBITDA Margin for Q1 2026 stood at 2.69%, down from 12.91% in the prior quarter.
• The five-year high for EBITDA Margin was 12.91% in Q4 2025, with the low at 152.9% in Q1 2022.
• Historically, EBITDA Margin has averaged 37.88% across 5 years, with a median of 30.11% in 2023.
• Annual changes were most pronounced in 2022 — EBITDA Margin jumped 20564 bps — and 2024, when it plunged 381 bps.
• Xeris Biopharma Holdings' EBITDA Margin stood at 38.97% in 2022, then advanced by 23 bps to 30.11% in 2023, then surged by 72 bps to 8.52% in 2024, then soared by 252 bps to 12.91% in 2025, then sank by 79 bps to 2.69% in 2026.
• The last three EBITDA Margin figures came in at 2.69% (Q1 2026), 12.91% (Q4 2025), and 0.83% (Q3 2025), per Business Quant data.